Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597027 | 0.88 | CARM1 (0.40) | ROCK2DRD2ROCK1 | |
| SCHEMBL5597043 | 0.86 | PIK3CD (0.38) | — | |
| SCHEMBL5596563 | 0.84 | DRD2 (0.40) | OPRK1ROCK2DRD2ROCK1DRD3 | |
| SCHEMBL5596515 | 0.84 | DRD2 (0.39) | ROCK2DRD2ROCK1DRD3 | |
| SCHEMBL5596712 | 0.84 | DRD2 (0.33) | ROCK2DRD2ROCK1DRD3 | |
| SCHEMBL5596494 | 0.83 | DRD2 (0.36) | ROCK2DRD2ROCK1DRD3 | |
| SCHEMBL5596830 | 0.83 | DRD2 (0.36) | ROCK2DRD2ROCK1DRD3 | |
| SCHEMBL5596548 | 0.83 | PIK3CD (0.35) | — | |
| SCHEMBL5596993 | 0.82 | DRD2 (0.36) | OGFRL1ROCK2DRD2ROCK1 | |
| SCHEMBL5596645 | 0.82 | DRD2 (0.40) | ROCK2DRD2ROCK1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | OPRL1 712/4885OGFRL1 1112/4885OPRM1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.